Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06635798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

StatusUnknown
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 10, 2024 (before its estimated December 4, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare the efficacy and safety of GR2001 injection with Human Tetanus Immunoglobulin(HTIG) in tetanus prophylaxis. Patients will receive either GR2001 injection or HTIG on study D0.
Trial Details
NCT Number NCT06635798
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Tetanus
Related terms Tetanus
Enrollment 582 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov